Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-10-22
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of and how well neratinib works in treating
older patients with stage IV HER2-positive breast cancer. Neratinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
City of Hope Medical Center
Collaborators:
National Cancer Institute (NCI) Puma Biotechnology, Inc.